Literature DB >> 26123860

Corticosteroids for the treatment of human infection with influenza virus: a systematic review and meta-analysis.

J-W Yang1, L-C Fan2, X-Y Miao2, B Mao1, M-H Li1, H-W Lu2, S Liang2, J-F Xu3.   

Abstract

Administration of corticosteroids to patients affected by influenza virus, especially pandemic avian influenza virus, although relatively common, remains controversial. A systematic review and meta-analysis was performed to assess the impact of corticosteroid treatment on outcomes of patients with influenza virus infection. The PubMed, EMBASE, Web of Science and Cochrane Library databases were searched up to February, 2015. Studies comparing corticosteroid treatment with no corticosteroid treatment in patients with influenza virus infection were included. The primary outcomes assessed were the association of mortality and nosocomial infection with corticosteroid treatment. Two authors independently extracted the data. ORs and weighted mean differences (WMDs) were used to describe dichotomous data and continuous data, respectively. Nineteen studies with 4916 patients were included in this meta-analysis. The results showed that corticosteroid treatment was significantly associated with mortality (OR 1.98, 95% CI 1.62-2.43, p < 0.00001) and nosocomial infection (OR 3.16, 95% CI 2.09-4.78, p < 0.00001). The durations of mechanical ventilation (WMD 3.82, 95% CI 1.49-6.15, p 0.001) and intensive-care unit stay (WMD 4.78, 95% CI 2.27-7.29, p 0.0002) were both markedly longer in the corticosteroid treatment group than in the control group. These findings suggest that routine steroid use may not be ideal for influenza virus infection. However, these results are derived from observational studies, with some important biases. They should be examined in future sufficiently powered randomized trials.
Copyright © 2015 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Corticosteroid; infection; influenza virus; meta-analysis; treatment; viral pneumonia

Mesh:

Substances:

Year:  2015        PMID: 26123860     DOI: 10.1016/j.cmi.2015.06.022

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  27 in total

1.  Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa.

Authors:  Timothy M Uyeki; Henry H Bernstein; John S Bradley; Janet A Englund; Thomas M File; Alicia M Fry; Stefan Gravenstein; Frederick G Hayden; Scott A Harper; Jon Mark Hirshon; Michael G Ison; B Lynn Johnston; Shandra L Knight; Allison McGeer; Laura E Riley; Cameron R Wolfe; Paul E Alexander; Andrew T Pavia
Journal:  Clin Infect Dis       Date:  2019-03-05       Impact factor: 9.079

2.  Corticosteroids for Community-Acquired Pneumonia: Overstated Benefits and Understated Risks.

Authors:  Grant Waterer; Mark L Metersky
Journal:  Chest       Date:  2019-07-06       Impact factor: 9.410

3.  Eosinophils Promote Antiviral Immunity in Mice Infected with Influenza A Virus.

Authors:  Amali E Samarasinghe; Rossana C N Melo; Susu Duan; Kim S LeMessurier; Swantje Liedmann; Sherri L Surman; James J Lee; Julia L Hurwitz; Paul G Thomas; Jonathan A McCullers
Journal:  J Immunol       Date:  2017-03-10       Impact factor: 5.422

4.  Pulmonary Impairment after Respiratory Viral Infections Is Associated with High Mortality in Allogeneic Hematopoietic Cell Transplant Recipients.

Authors:  Ajay Sheshadri; Roy F Chemaly; Amin M Alousi; Pankil K Shah; Gabriela Rondon; Lara Bashoura; Joumana Kmeid; Jacques Azzi; David W Blanco; Maryam Kaous; Burton F Dickey; Richard E Champlin; Dimpy P Shah
Journal:  Biol Blood Marrow Transplant       Date:  2018-12-03       Impact factor: 5.742

5.  Corticosteroids as adjunctive therapy in the treatment of influenza.

Authors:  Louise Lansbury; Chamira Rodrigo; Jo Leonardi-Bee; Jonathan Nguyen-Van-Tam; Wei Shen Lim
Journal:  Cochrane Database Syst Rev       Date:  2019-02-24

Review 6.  Assessing the State of Knowledge Regarding the Effectiveness of Interventions to Contain Pandemic Influenza Transmission: A Systematic Review and Narrative Synthesis.

Authors:  Patrick Saunders-Hastings; Jane Reisman; Daniel Krewski
Journal:  PLoS One       Date:  2016-12-15       Impact factor: 3.240

7.  Predictors for fatal human infections with avian H7N9 influenza, evidence from four epidemic waves in Jiangsu Province, Eastern China, 2013-2016.

Authors:  Wang Ma; Haodi Huang; Jian Chen; Ke Xu; Qigang Dai; Huiyan Yu; Fei Deng; Xian Qi; Shenjiao Wang; Jie Hong; Changjun Bao; Xiang Huo; Minghao Zhou
Journal:  Influenza Other Respir Viruses       Date:  2017-07-26       Impact factor: 4.380

8.  The endotoxin-induced pulmonary inflammatory response is enhanced during the acute phase of influenza infection.

Authors:  R M Koch; D A Diavatopoulos; G Ferwerda; P Pickkers; M I de Jonge; M Kox
Journal:  Intensive Care Med Exp       Date:  2018-07-05

Review 9.  Could Histamine H1 Receptor Antagonists Be Used for Treating COVID-19?

Authors:  Changbo Qu; Gwenny M Fuhler; Yihang Pan
Journal:  Int J Mol Sci       Date:  2021-05-26       Impact factor: 5.923

10.  Immunomodulatory therapy, risk factors and outcomes of hospital-acquired bloodstream infection in patients with severe COVID-19 pneumonia: a Spanish case-control matched multicentre study (BACTCOVID).

Authors:  Gabriela Abelenda-Alonso; Alexander Rombauts; Carlota Gudiol; Isabel Oriol; Antonella Simonetti; Ana Coloma; Alejandro Rodríguez-Molinero; Elisenda Izquierdo; Vicens Díaz-Brito; Montserrat Sanmartí; Ariadna Padullés; Inmaculada Grau; Mar Ras; Alba Bergas; Lluïsa Guillem; Alejandro Blanco-Arévalo; Claudia Alvarez-Pouso; Natalia Pallarés; Sebastián Videla; Cristian Tebé; Jordi Carratalà
Journal:  Clin Microbiol Infect       Date:  2021-07-07       Impact factor: 8.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.